BIONTECH SE SPON. ADRS 1
Commented by Stefan Feulner on November 9th, 2020 | 10:50 CET
BioNTech, Defense Metals, Bayer: Earn money countercyclically
It is complete. After a tense struggle and four days of counting votes, Joe Biden is declared the 46th President of the United States of America. So the Twitter tirades of the defeated Donald Trump should be history. The traces Trump left behind during his four-year reign, however, are likely to keep the government busy for some time to come. Some things, such as the withdrawal from the climate agreement, can be quickly repaired. Biden will carefully weigh up what is "in" and what is "out" on different points of the "America First" program imposed by the predecessor.
Read
Commented by Stefan Feulner on October 30th, 2020 | 09:37 CET
BioNTech, Newlox Gold, NEL ASA - get in now!
Germany in a state of shock! After the announcement of a second lockdown and a steadily increasing number of infections, the calls for a vaccine against coronavirus are getting louder and louder. The question is not when, but how quickly it will be available, especially for risk groups. Three Companies are currently heading for the home stretch. The first mover will not only get fame and recognition, but the market value of the Company will go through the roof. After the strong sell-off on the world's stock markets, there are lucrative entry opportunities.
Read
Commented by Stefan Feulner on October 21st, 2020 | 12:42 CEST
BioNTech, Valeo Pharma, Pfizer - Starting signal!
Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.
Read
Commented by Nico Popp on October 16th, 2020 | 12:19 CEST
CureVac, BioNTech, Valeo Pharma: Where is there still potential?
The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
Read
Commented by Stefan Feulner on October 15th, 2020 | 13:16 CEST
Bayer, Triumph Gold, BioNTech - decisive phase!
Almost everyone knows the philosophies proclaimed by the great and wise stock market gurus. “Never try catch a falling knife" or "buy on the sound of cannons, sell on the sound of trumpets”. What is true? In the case of Bayer, after the Monsanto disaster, possibly higher than planned fines and a cracking profit warning, one might think that everything has already been priced in. However, it is still not known how and when the Monsanto disaster will end. The fact is, there are other, more appealing papers at the moment ...
Read
Commented by Stefan Feulner on October 14th, 2020 | 11:40 CEST
BioNTech, BIGG, Bitcoin - The traffic lights are green!
A trend is present when the price of security tends to move in a specific direction, even under fluctuation. To play this trend correctly and to make more significant price gains, one should recognize the signals of a trend reversal. With Bitcoin & Co., this could soon be the case. The stabilization phase is still underway, but buying pressure has increased in the last few days. Companies that have a unique position in the crypto market could benefit from this.
Read
Commented by Stefan Feulner on October 9th, 2020 | 12:37 CEST
BioNTech, Barrick Gold, Velocity Minerals - Golden Times!
No! The end of the gold price increase has yet to be reached. The problems, which have become even more acute in recent months due to the pandemic, will not disappear overnight. It is understandable that the price of the precious metal will briefly collapse because "Big Donald" is saluting himself, or the helicopter pilot who brought him safely back to the White House after his short, three-day intermezzo in the military hospital. He wants to show that he has quickly left Corona behind him. However, among his many headwinds, the President now faces the US election, the still high number of Covid-19 cases in the US, the rapidly increasing national debt, and the unchecked money printing of the central banks. At least in terms of case numbers, there is positive news from BioNTech. The Corona vaccine candidate, developed by the Mainz-based company, is entering the approval phase.
Read
Commented by Mario Hose on September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.
Read
Commented by Mario Hose on September 28th, 2020 | 10:15 CEST
BioNTech, NEL ASA, Silver Viper: Profit lies in purchasing
As is well known, timing is of paramount importance for the stock market. Investors who look to take a position always look for the best possible entry point. Rarely do even experienced stock market traders succeed in hitting the low point before the price rises. In connection with the current Corona Pandemic and the uncertainties as to how the course of a possible second wave of infection will develop, there have already been considerable price fluctuations and entry opportunities on the stock markets in recent weeks.
Read
Commented by Mario Hose on September 23rd, 2020 | 09:05 CEST
BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?
When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.
Read